| scholarly article | Q13442814 |
| P2093 | author name string | Ying Yan | |
| Surinder K Batra | |||
| Apar K Ganti | |||
| Maneesh Jain | |||
| Suprit Gupta | |||
| Satyanarayana Rachagani | |||
| Chittibabu Guda | |||
| Moorthy P Ponnusamy | |||
| Dhanya Haridas | |||
| Parthasarathy Seshacharyulu | |||
| Imayavaramban Lakshmanan | |||
| Suhasini Joshi | |||
| P2860 | cites work | Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab | Q24313194 |
| Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries | Q24563818 | ||
| Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera | Q24595150 | ||
| Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src | Q24614033 | ||
| The Pfam protein families database | Q24619716 | ||
| MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells | Q24630950 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Structure of the extracellular region of HER3 reveals an interdomain tether | Q27639450 | ||
| HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models | Q27853067 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins | Q28208031 | ||
| Multiple Grb2-protein complexes in human cancer cells | Q28302172 | ||
| Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 | ||
| Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration | Q30155572 | ||
| Role of Grb2 in EGF-stimulated EGFR internalization. | Q30165476 | ||
| Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma | Q30430971 | ||
| A top-down approach to infer and compare domain-domain interactions across eight model organisms | Q33424520 | ||
| ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency | Q33963261 | ||
| Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells | Q33994268 | ||
| Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. | Q34292705 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma | Q34582105 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Examination of HER3 targeting in cancer using monoclonal antibodies | Q35031462 | ||
| MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells | Q35035434 | ||
| Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells | Q36206219 | ||
| Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. | Q36437150 | ||
| Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells | Q36610877 | ||
| Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members | Q36643816 | ||
| HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. | Q36957145 | ||
| The ERBB3 receptor in cancer and cancer gene therapy | Q37135372 | ||
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 | ||
| Molecular pathways: HER3 targeted therapy | Q38187398 | ||
| Transcriptional regulation of human mucin gene MUC4 in pancreatic cancer cells | Q39799111 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. | Q40150208 | ||
| Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. | Q40671576 | ||
| HER3 overexpression and survival in solid tumors: a meta-analysis | Q43659959 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma | Q44645468 | ||
| Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. | Q46047974 | ||
| Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression | Q46119162 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma | Q48704352 | ||
| HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. | Q53142393 | ||
| Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms | Q71048246 | ||
| MUC4 expression increases progressively in pancreatic intraepithelial neoplasia | Q74385664 | ||
| Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma | Q81341144 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 21085-21099 | |
| P577 | publication date | 2015-05-16 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells | |
| P478 | volume | 6 |
| Q64951879 | Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells. |
| Q33884794 | Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis |
| Q41859754 | Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer |
| Q37706759 | Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas |
| Q26739942 | Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling) |
| Q37174016 | Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation |
| Q37164549 | MUC4 is negatively regulated through the Wnt/β-catenin pathway via the Notch effector Hath1 in colorectal cancer |
| Q38688917 | MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. |
| Q38804960 | MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling. |
| Q39410445 | Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy |
| Q37705843 | NIDO, AMOP and vWD domains of MUC4 play synergic role in MUC4 mediated signaling |
| Q36917818 | PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. |
| Q58803127 | Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer |
| Q42148898 | Prognostic significance of HER3 in patients with malignant solid tumors |
| Q36540519 | The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma |
| Q64067178 | Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs |
Search more.